Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 10:36:11308.
doi: 10.3389/ti.2023.11308. eCollection 2023.

Prevalence and Patient-Level Correlates of Intentional Non-Adherence to Immunosuppressive Medication After Heart-Transplantation-Findings From the International BRIGHT Study

Affiliations

Prevalence and Patient-Level Correlates of Intentional Non-Adherence to Immunosuppressive Medication After Heart-Transplantation-Findings From the International BRIGHT Study

Mark T Marston et al. Transpl Int. .

Abstract

After heart transplantation (HTx), non-adherence to immunosuppressants (IS) is associated with poor outcomes; however, intentional non-adherence (INA) is poorly understood regarding its international variability in prevalence, contributing factors and impact on outcomes. We investigated (1) the prevalence and international variability of INA, (2) patient-level correlates of INA, and (3) relation of INA with clinical outcomes. Secondary analysis of data from the BRIGHT study-an international multi-center, cross-sectional survey examining multi-level factors of adherence in 1,397 adult HTx recipients. INA during the implementation phase, i.e., drug holiday and dose alteration, was measured using the Basel Assessment of Adherence to Immunosuppressive Medications Scale© (BAASIS©). Descriptive and inferential analysis was performed with data retrieved through patient interview, patient self-report and in clinical records. INA prevalence was 3.3% (n = 46/1,397)-drug holidays: 1.7% (n = 24); dose alteration: 1.4% (n = 20); both: 0.1% (n = 2). University-level education (OR = 2.46, CI = 1.04-5.83), insurance not covering IS costs (OR = 2.21, CI = 1.01-4.87) and barriers (OR = 4.90, CI = 2.73-8.80) were significantly associated with INA; however, clinical outcomes were not. Compared to other single-center studies, this sample's INA prevalence was low. More than accessibility or financial concerns, our analyses identified patient-level barriers as INA drivers. Addressing patients' IS-related barriers, should decrease INA.

Keywords: correlates; heart transplantation; immunosuppression; intentional non-adherence; medication non-adherence.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Process of medication adherence illustrating phases in which intentional non-adherence and intentional implementation non-adherence (i.e., drug holiday and dose alteration) may appear [3].
FIGURE 2
FIGURE 2
Modified integrative model of behavioral prediction [34, 35].
FIGURE 3
FIGURE 3
Prevalence of intentional non-adherence internationally. Sample, N (%): Australia, 51 (3.7); Switzerland, 47 (3.4); UK, 99 (7.1); Belgium, 74 (5.3); France, 158 (11.5); Spain, 223 (16.2); Italy, 109 (7.9); Germany, 65 (4.8); Canada, 119 (8.7); USA, 337 (24.3); Brazil, 100 (7.2). Missings: France, 1.3%; Spain, 1.8%; Italy, 1.8%; Germany, 3.0%; Canada, 1.7%; USA, 0.9%; Mean, 1.0%.

Similar articles

Cited by

References

    1. Wilhelm MJ. Long-term Outcome Following Heart Transplantation: Current Perspective. J Thorac Dis (2015) 7:549–51. 10.3978/j.issn.2072-1439.2015.01.46 - DOI - PMC - PubMed
    1. De Geest S, Denhaerynck K, Dobbels F. Clinical and Economical Consequences of Nonadherence to Immunosuppressive Drugs in Adult Solid Organ Transplantation (Invited Editor: Dr. Federico Oppenheime). In: Grinyò DJ, editor. International Transplantation Updates 2011. Barcelona, Spain: Permanyer Publications; (2011). p. 63–81.
    1. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A New Taxonomy for Describing and Defining Adherence to Medications. Br J Clin Pharmacol (2012) 73:691–705. 10.1111/j.1365-2125.2012.04167.x - DOI - PMC - PubMed
    1. van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J, et al. Furthering Patient Adherence: a Position Paper of the International Expert Forum on Patient Adherence Based on an Internet Forum Discussion. BMC Health Serv Res (2008) 8:47. 10.1186/1472-6963-8-47 - DOI - PMC - PubMed
    1. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding Patients' Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: a Meta-Analytic Review of the Necessity-Concerns Framework. PLoS One (2013) 8:e80633. 10.1371/journal.pone.0080633 - DOI - PMC - PubMed

Substances